Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
| العنوان: | Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data |
|---|---|
| المؤلفون: | Roman Hájek, Vladimir Maisnar, I. Agirrezabal, Luděk Pour, Sebastian Gonzalez-McQuire, Jiri Minarik, Ivan Spicka, P. Jandova, Marco Campioni |
| المصدر: | The European Journal of Health Economics |
| بيانات النشر: | Springer Berlin Heidelberg, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Palliative care, Cost effectiveness, Cost-Benefit Analysis, Economics, Econometrics and Finance (miscellaneous), Registry of Monoclonal Gammopathies, Dexamethasone, Disease-Free Survival, Drug Costs, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Multiple myeloma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Registries, Lenalidomide, Survival analysis, ASPIRE, Czech Republic, Original Paper, business.industry, Health Policy, Carfilzomib, Real world, medicine.disease, I19, Discontinuation, chemistry, 030220 oncology & carcinogenesis, Cost-effectiveness, Quality-Adjusted Life Years, Neoplasm Recurrence, Local, business, Incremental cost-effectiveness ratio, Oligopeptides, medicine.drug |
| الوصف: | ObjectiveTo predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies.MethodsA partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources.ResultsThe base case incremental cost effectiveness ratio for KRd compared with Rd was €73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of €117,534 over their lifetime compared with €53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively.ConclusionsCombining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system. |
| اللغة: | English |
| تدمد: | 1618-7601 1618-7598 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd614268e91592797a30f671d424a2aTest http://europepmc.org/articles/PMC7072050Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0bd614268e91592797a30f671d424a2a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16187601 16187598 |
|---|